Emavusertib

Near Add Your Location

Sorting 1 by

Accepting patients

TakeAim

TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • IRAK 4 Inhibitor
  • Phase 1/2
  • Has results